Drug Pipeline

Cediranib Maleate Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
14
Active Studies
1
Recruiting
2
Phase 3
4
Top Sponsors
1
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-05-29 NCT02893917
Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug…		 date change Completion pushed: 2026-06-18 -> 2027-05-31
Active Studies by Phase
Phase 3
1
Phase 2/3
1
Phase 2
7
Phase 1/2
3
Phase 1
2
Active Trials
NCT IDTitleConditionStatus
Phase 3
NCT02446600 Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib… Fallopian Tube Clear Cell Adenocarcinoma Active, Not Recruiting
Phase 2/3
NCT02502266 Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or… Fallopian Tube Clear Cell Adenocarcinoma Active, Not Recruiting
Phase 2
NCT04090567 Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline… Advanced Breast Carcinoma Recruiting
NCT03851614 Study of DNA Damage, Angiogenesis, and PD-L1 Inhibitors in Advanced Solid Tumors Mismatch Repair Proficient Colorectal Cancer Active, Not Recruiting
NCT02498613 A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors Advanced Malignant Solid Neoplasm Active, Not Recruiting
NCT02345265 Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian… Fallopian Tube Carcinoma Active, Not Recruiting
NCT02893917 Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug… Advanced Prostate Adenocarcinoma With Neuroendocrine Differentiation Active, Not Recruiting
NCT04739800 Comparison of Standard of Care Treatment With a Triplet Combination of Targeted… Fallopian Tube Mucinous Adenocarcinoma Active, Not Recruiting
NCT03660826 Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib… Endometrial Adenocarcinoma Active, Not Recruiting
Phase 1/2
NCT02484404 Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in… Colorectal Neoplasms Active, Not Recruiting
NCT01116648 Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian… Fallopian Tube Carcinoma Active, Not Recruiting
NCT01064648 Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients… Epithelioid Mesothelioma Active, Not Recruiting
Phase 1
NCT01364051 Cediranib Maleate and Selumetinib Sulfate in Treating Patients With Solid Malignancies Metastatic Melanoma Active, Not Recruiting
NCT00750841 Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of… Solid Tumors Active, Not Recruiting
Sponsors Running Cediranib Maleate Trials
National Cancer Institute (NCI) (11) AstraZeneca (1) University Health Network, Toronto (1) M.D. Anderson Cancer Center (1)
Disease Areas
Breast Cancer (4) Ovarian Cancer (4) Sarcoma (3) Colorectal Cancer (2) Mesothelioma (1) Melanoma (1) Non-Small Cell Lung Cancer (NSCLC) (1) Small Cell Lung Cancer (1) Pancreatic Cancer (1) Prostate Cancer (1)
Get alerts when Cediranib Maleate trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free